Timo Bey (貝天慕)’s Post

#Japan’s #NextPhase in #MedicalResearchAndDevelopment: The Japanese government has unveiled its "Third Phase Medical Research Development Plan", emphasizing clear targets and measurable indicators to drive progress in medical R&D. This step is essential to ensuring accountability and tracking success effectively. 🧬📊 A key highlight is the plan's focus on accelerating the practical application of research outcomes, bridging the gap between innovation and implementation. This aims to foster #TechnologyTransfer and translate #Research into tangible solutions that benefit society. 🚀💡 The plan also acknowledges Japan's declining global position in medical research, with a renewed urgency to address this through improved policies and international collaboration. This demonstrates a commitment to revitalizing Japan’s competitiveness in the field. 🌍📈 However, critical details are still missing, including specifics on budget allocations, priority research areas, and mechanisms for technology transfer and commercialization. These are crucial for ensuring the plan’s success and making a global impact. ❓⚙️ More details at #ScienceNews: https://lnkd.in/gy_nmZMa #InnovativeJapan #MedicalScience #MedicalInnovation #ResearchAndDevelopment #GlobalHealth #SciencePolicy #JapanResearch

Thrilled to share article from La Vanguardia detailing a recent trip to Shenzhen by a small group of forward-thinking Catalan businessmen and businesswomen. This journey, aimed at fostering innovation and exploring new business opportunities, has been a significant step towards strengthening ties between Catalonia and China. What makes this article particularly special for us is the participation of our Managing Partner, Josep Ll. Sanfeliu. His presence in this delegation underscores our commitment to global collaboration and staying at the forefront of technological and business advancements. The article reflects the impressive development of China in the areas of health technology, innovation both in medtech and in biotech. The visit to the country and to Shenzhen perfectly exemplifies where the future of healthcare is going and Asabys Partners is trying to capture those technologies in its investment activity since it's just a window to the future of healthcare. China still represents an opportunity but also faces many challenges ahead in managing its own healthcare needs and social coverage for its population. In summary, healthcare innovation, technology and the need to invest in that space is key for the future of society.

- 🌏 Geopolitical tensions prompt healthcare firms to move from China to Southeast Asia, offering cost-effective solutions. - 💰 GL Capital aims to fund these expansions, lowering barriers for small to medium enterprises in the sector. - 🤝 The collaboration promises mutual benefits, leveraging China's advanced medical tech and Southeast Asia's market potential. - Want full insights? Subscribe to Tech in Asia to read the entire article.

🌏 Breaking down barriers: the potential of the Chinese Healthcare Market for Finnish companies - an eye opener. At Targenta Ltd., we strive to learn, not just attend events. That’s why I’m excited to share actionable insights from the recent Navigating China's Health Opportunities webinar by Nordic Life Science Platform - Fast-track China Entry. Instead of the usual “We’re thrilled to participate,” let me take you through the key learnings. 🎯 📊 #1 Business Finland’s Overview (Presented by: Sanorita Li , Business Finland ) 👉 Growth Opportunities: China’s health sector is expanding rapidly, with innovations in biomedicine, medtech, digital health, and agetech. 👉 Market Trends: Policies are favoring foreign hospitals and gene therapy tech in free trade zones like Beijing and Shanghai. 👉 Challenges: Policy pressures, including volume-based procurement and anti-corruption measures, demand agile approaches. 👨⚕️ #2 Fast-Track Market Access for Medical Products (Presented by: Sharon Xu , NLSP) 👉 Hainan Boao Lecheng Zone (HBL): Early access for CE/FDA-approved medical devices and real-world data studies to fast-track approvals in mainland China. 👉 Advantages: Direct sales, tax exemptions, and early brand exposure without NMPA approvals. 👉 Top Players Engaging: Finland is well-placed with 11 innovative solutions already fast-tracked here. 📈 #3 Chinese Healthcare Market Trends & Policies (Presented by: Noam David Stern 星诺 NLSP) 👉 Demographic Shifts: An aging population is driving demand for chronic disease solutions. 👉 Spending Surge: Healthcare investment is set to double to $2.4 trillion by 2030. 👉 Key Strategies: ‘Healthy China 2030’ prioritizes disease prevention, digitization, and AI-driven healthcare. 🚀 #4 Step-by-Step Market Entry Model (Presented by: Noam David Stern, NLSP) 👉 Barriers Simplified: NLSP guides companies through legal, cultural, and logistical challenges with services like IPR protection, hospital matchmaking, and CRO selection. 👉 Strategic Areas: HBL and the Guangdong-Hong Kong-Macao Great Bay Area (GBA) serve as gateways for Nordic innovation. 🤝 Special Thanks to: Business Finland and Sanorita Li for insights into Finland-China collaborations. Sharon Xu and Noam David Stern of NLSP for breaking down market intricacies and the incredible Finnish health delegation paving the way for innovation. 💡 At Targenta, this knowledge is steering us toward our 2025 goal: introducing PharmaSolv, our tailored medication optimizer app, to different susceptible markets 🌟 Let’s turn these learnings into action! #Innovation #ChinaHealthcare #HealthTech #Pharma #MarketEntry #GlobalGrowth #Targenta Iiro Uotila Health Incubator Helsinki

🇹🇼 Taiwan Medical-Technology Innovation Exploring the realm of technological innovations in Taiwan, particularly in the medical field, has been an enlightening experience. During a recent exchange with MedTech entrepreneurs, I was captivated by their commitment to advancing healthcare solutions through cutting-edge technology. 🌟 Taiwan is rapidly becoming a hub for medical innovation, with a strong focus on AI-enhanced surgical systems and minimally invasive procedures. These innovations not only enhance surgical accuracy but also significantly improve patient outcomes, demonstrating Taiwan's potential to revolutionize healthcare on a global scale. 🤖 Our discussions highlighted the importance of collaboration and partnership as we aim to expand these innovative solutions into the European market. The Taiwanese entrepreneurs are eager to share their expertise and technology, fostering a mutually beneficial relationship that can enhance healthcare delivery in Europe. By combining our strengths, we can create a powerful synergy that drives advancements in medical technology across borders. 🤝 As we move forward, I am excited about the possibilities that lie ahead. Together, we can harness the power of innovation to address pressing healthcare challenges and improve patient care worldwide. Here’s to a future filled with collaboration and transformative solutions! 🌍💖 #asia #expansion #innovation #scaleup #geoeconomics

🚀 China's medical device sector is booming! 🚀 China has rapidly climbed to become the world's second-largest hub for medical devices. With an impressive average compound annual growth rate of 10.54% over the last five years, the nation is revolutionizing global healthcare. Key highlights: Innovation and Efficiency: Streamlined approval processes have led to 217 high-tier innovative devices receiving approval, including game-changers like brain pacemakers and artificial blood vessels. Global Impact: Many of these devices, once reliant on foreign imports, are now integrated into clinical use in China, driving significant medical advancements. Fast-Tracked Drug Approvals: Over 100 drugs gain market approval annually, focusing on critical needs like pediatric and rare disease treatments. China's commitment to medical innovation and efficient approval processes is paving the way for groundbreaking advancements in healthcare. 🌐💉 #HealthcareInnovation #MedicalDevices #ChinaTech #GlobalHealth

#Mirxes is honoured and delighted to be the only life sciences company hosting Mr Paul Chan, Hong Kong's Financial Secretary, during his visit to Hangzhou and Suzhou last week. Our Co-Founders, Dr Lihan Zhou (CEO) and Dr Zou Ruiyang (CTO), shared our growth journey from Singapore start-up to becoming a leader in precision medicine through #innovation, #commercialisation, #internationalisation, and strong public-private partnerships. We also showcased our maturing clinical pipeline, advanced facilities, and plans to expand market share in Northeast Asia with our early cancer detection products, anchored by our existing presence in Hangzhou and Hong Kong. We were impressed by Mr Chan's insights into Hong Kong's economic transformation, particularly the focus on Life and Health Technology as one of their four strategic industries. This aligns perfectly with Mirxes' mission to accelerate access to novel and life-saving cancer diagnostics for the vast 2.4 billion population across Northeast and Southeast Asia. Mr Chan also shared about the Office for Attracting Strategic Enterprises (OASES) and the HK$30 billion “Co-Investment Fund” under Hong Kong Investment Corporation to attract strategic enterprises to invest and operate in Hong Kong. We believe strongly in Singapore and Hong Kong’s critical and synergistic roles in driving life sciences innovation, commercialisation, and capital market access, for the benefit of the region and the populations under-served by precision medicine.  Mirxes is committed to saving lives and reducing healthcare burden through early detection, leveraging the strength of the Singapore and Hong Kong ecosystems. #preventivehealthcare #precisionmedicine #biotech #cancerearlydetection #earlydetection #earlydetectionsaveslives #innovation #globalpartnership #publicprivatepartnership

Calling businesses in the #MedTech and #Diagnostics sector. The Innovate UK Global Business Innovation Programme focused on Singapore is open for applications. 🇬🇧 🇸🇬 Why Singapore? With the Asia-Pacific Medical Technology (MedTech) market expected to grow to US$225 billion by 2030, Singapore is strategically placed to enable companies to tap into these regional opportunities, and Singapore’s network of top universities, research institutions and innovative start-ups also enable MedTech companies to fully engage with a vibrant open innovation ecosystem. 🤝 Click the link below to find out more and apply for this exciting #GBIP: 🔗https://bit.ly/3VHm3PF #InnovateUK #MedTech #ukinsingapore

🌎 Exciting insights from the 15th INTERPAT Innovation Seminar, highlighting Latin America's strong ambition to drive life sciences innovation. Leaders across the region are committed to fostering a dynamic environment that attracts, retains, and rewards talent—ultimately enhancing both societal health and economic prosperity. Key takeaways from the discussions: ·       Strengthening IP Protection: Making sure intellectual property protection keeps pace with Argentina's and Latin America's growing innovation ambitions will be crucial for sustained progress. ·       Championing Progress: Countries that prioritize and protect innovative progress will inevitably outpace those that don’t. ·       Transforming Research into Impact: It's vital to advance Research AND Development initiatives, ensuring that scientific breakthroughs move beyond publications and create real-world benefits. ·       Collaboration Across Sectors: Governments must cultivate an environment where academia collaborates closely with both global and local innovators, enabling shared technology, knowledge, and expertise. ·       Prioritizing Data Protection: Protecting data that is created from complex and costly clinical trials remains essential to fostering continued investment and innovation. ·       Reforming Patentability Guidelines: Modernizing Argentina’s patent guidelines is key to incentivizing innovation, so that innovative progress receives the reward it needs to benefit patients today and secure investment for patients tomorrow. ·       Rethinking Compulsory Licensing: Compulsory licensing undermines trust and often fails to improve access. There is a need to explore collaborative, win-win approaches so that the virtuous cycle of innovation and access grows from strength to strength. By driving these changes, Latin America is paving the way for a future where life sciences innovation thrives, enhancing the lives of patients and bolstering the regional economy. A special thank you to Roberto Ribeiro, Monica Lupi, Gonzalo Rovira, Corey Salsberg, Jon Santamauro, Dr. Jörg Thomaier, @Bettina Wanner, Fernando Portugal, Anjam Aziz, Maria Isabel Giacchetti de Moraes, Maria L. Vazquez, Carlos Felipe Escobar Roa, Raquel Sorza Ocaña, Ana Carolina Cagnoni, and many others for their invaluable contributions. #Innovation #LifeSciences #LatinAmerica #EconomicGrowth #IntellectualProperty #ResearchAndDevelopment #PatientCare #Collaboration #HealthTech #ClinicalResearch #PatentReform #InnovationEcosystem #TalentRetention #FutureOfHealth

🌟Charles River Associates had a great opportunity to support EFPIA - European Federation of Pharmaceutical Industries and Associations and collaborate with their team on developing a Competitiveness Strategy for European Life Sciences. This initiative is timely and vital for maintaining Europe's leadership in the sector. EFPIA is proposing five recommendations that can help Europe take a new approach to its life sciences ecosystem; one that prioritises connecting the sector and securing EU competitiveness. Key recommendations:   🏛️ The creation of an EU Office for Life Sciences and a dedicated Competitiveness strategy for European Life Sciences 🌐 A European eco-system that can transform ideas into innovation ⚙️ Develop a globally competitive location for developing and manufacturing new technologies 🏥 Invest in health 🌍 Secure Europe’s place as a resilient global biopharma player At this pivotal moment, the EU can turn challenges into opportunities, making Europe a leader in life sciences. Policymakers must unite behind an ambitious strategic vision for the LS sector to achieve a more competitive, healthier, and stronger Europe. 🚀 Link: https://lnkd.in/dc6kavDE #CRA #LifeSciences #EFPIA #Pharma